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Manuscript
 
Joe Bilcke and colleagues investigated the cost-effectiveness of alternative 
delivery strategies for typhoid Vi-conjugate vaccine (TCV) in each of the 54 
countries eligible for financial support from Gavi, the Vaccine Alliance. In settings 
with high Salmonella enterica serovar Typhi incidence, an approach of routine 
vaccination of infants plus a catch-up campaign to the age of 15 years seems 
cost-effective and would reduce the number of cases in Zimbabwe by 68% over 
the next 10 years. 1 
 
Recently Zimbabwe conducted a one-off mass TCV vaccination campaign funded 
by Gavi targeting children 6 months to 15 years of age in communities affected 
by an on-going typhoid outbreak.2 This has been the first use of TCV and the first 
typhoid outbreak response vaccination campaign in Africa. The present and past 
outbreaks of cholera and typhoid are a terrible consequence of Zimbabwe’s 
failure to invest in and manage both its basic water and sanitation infrastructure 
and its health care system.3 In addition, dilapidated infrastructure, lack of 
diagnostics and drugs, brain drain, prohibitive user fees in health facilities and 
strikes by medical personnel have contributed to most recent outbreak of 
typhoid..  
FIEBRE (Febrile Illness Evaluation in a Broad Range of Endemicities, 
https://www.lshtm.ac.uk/research/centres-projects-groups/fiebre), a multi-
country study investigating the causes of fever in sub-Saharan Africa and 
southeast Asia has been enrolling adults and children presenting with fever at 
health facilities in Harare since June 2018. As part of the study, multiple 
diagnostic investigations are performed including; automated blood cultures, 
bacterial identification and drug susceptibility testing.  S. Typhi has been isolated 
from 23/133 and 38/183 blood culture in children and adults respectively.  Of 
the 61 S. Typhi isolates 54(88·5%) were multi-drug and 4 in 5 (80·3%) displayed 
diminished fluoroquinolone susceptibility. In the first three months after the 
vaccination campaign we observed a sharp decrease in one of the worst affected 
communitiesin the proportion of confirmed and suspected typhoid cases among 
children, but not adults (figure 1). 
 
While the TCV vaccination campaign seems highly effective in reducing the 
typhoid incidence among children, a more comprehensive approach such as 
vaccination of adults and WASH (Water, sanitation and hygiene) interventions 
will be needed to halt this and future typhoid outbreaks once established.  
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Figure 1 Confirmed and suspected S. Typhi cases according to age group and in 
relation to the TCV mass vaccination campaign 
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To the Editor in Chief 
Dr John McConnell 
The Lancet Infectious Diseases 
 
 
RE: Correspondence in response to the article entitled “Cost-effectiveness of routine and campaign use 
of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study” by Blicke et al. (May 23 2019) 
 
 
 
 
June 25th, 2019 
Dear Dr John McConnell 
Please find attached the correspondence entitled:  
“Use of typhoid Vi-conjugate vaccine for outbreak management in Zimbabwe” to be considered for 
publication in the Lancet Infectious Diseases in response to the article published by Blicke et al entitled 
Correspondence in response to the article entitled “Cost-effectiveness of routine and campaign use 
of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study”. 
We read with great interest the publication by Blicke et al estimating the effect of different typhoid 
conjugate vaccine (TCV) strategies using mathematical modeling. Earlier this year a TCV mass vaccination 
campaign was conducted in Zimbabwe in response to an ongoing typhoid outbreak. We report on the 
effect of TCV on Salmonella Typhi cases by comparing S. Typhi positive blood cultures in the period pre- 
and post vaccination.  
Our data emphasize the need for comprehensive strategies including vaccination of adults and children 
together with WASH interventions for outbreak control.  
We believe that these results are of interest to the readership of the Lancet infectious Diseases. The 
manuscript is not under evaluation elsewhere. All co-authors fulfil ICMJE criteria for authorship, have 
seen the final draft and approved the manuscript for submission for publication. 
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We hope that you find our manuscript of interest for publication in Lancet infectious Diseases and we are 
looking forward to your reply. 
 
Sincerely and on behalf of all authors 
Ioana D. Olaru 
 
